Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vaccination for CML Patients With Persistent Disease on Imatinib Mesylate

NCT00301093 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT00301093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00301093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vaccination for CML Patients With Persistent Disease on Imatinib Mesylate
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2005
Completion date
September 10, 2020
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia